CD79A
B-cell antigen receptor complex-associated protein alpha chain
Also known as: CD79A_HUMAN, Ig-alpha, IGA, IGAlpha, MB-1, MB1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P11912
- Gene
- CD79A
- Ensembl
- ENSG00000105369
- Chromosome
- 19
- Canonical length
- 226 aa
- Protein class
- Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-alpha protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
226 residues, UniProt reviewed canonical sequence.
>P11912|CD79A
1 MPGGPGVLQA LPATIFLLFL LSAVYLGPGC QALWMHKVPA SLMVSLGEDA HFQCPHNSSN
61 NANVTWWRVL HGNYTWPPEF LGPGEDPNGT LIIQNVNKSH GGIYVCRVQE GNESYQQSCG
121 TYLRVRQPPP RPFLDMGEGT KNRIITAEGI ILLFCAVVPG TLLLFRKRWQ NEKLGLDAGD
181 EYEDENLYEG LNLDDCSMYE DISRGLQGTY QDVGSLNIGD VQLEKPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CD79A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.49
- Highest tissue expression
- 510 nTPM
Expression across tissuesHPA
Tissue
- tonsil: 510 nTPM
- lymph node: 450 nTPM
- spleen: 306 nTPM
- appendix: 201 nTPM
- small intestine: 158 nTPM
- thymus: 87 nTPM
Single-cell type
- plasma cells: 687 nCPM
- b-cells: 684 nCPM
- gastric chief cells: 51 nCPM
- thymocytes: 42 nCPM
- foveolar cells: 31 nCPM
- parietal cells: 30 nCPM
Immune cell
- naive B-cell: 1,463 nTPM
- memory B-cell: 1,278 nTPM
- total PBMC: 63 nTPM
- plasmacytoid DC: 36 nTPM
- naive CD8 T-cell: 26 nTPM
- basophil: 13 nTPM
Brain region
- spinal cord: 1.2 nTPM
- medulla oblongata: 0.5 nTPM
- amygdala: 0.4 nTPM
- basal ganglia: 0.4 nTPM
- midbrain: 0.4 nTPM
- pons: 0.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CD79A.
Disease | AllUniProt
Conditions CD79A is implicated in, by any mechanism.
- Agammaglobulinemia 3, autosomal recessive (AGM3) MIM:613501
Disease | GeneticClinVar
8 pathogenic / likely-pathogenic of 185 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Agammaglobulinemia 3, autosomal recessive
- Inherited Immunodeficiency Diseases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.5
- gnomAD pLI
- 0.69
- gnomAD missense Z
- 1.13
- DepMap mean gene effect
- 0.14
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adaptive immune response
- B cell activation
- B cell differentiation
- B cell proliferation
- B cell receptor signaling pathway
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CD79A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CD79A as an antibody target. Whether an autoantibody or antibody against CD79A could matter depends on whether native CD79A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CD79A is annotated at the cell surface, where native CD79A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CD79A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...